Lilly COVID-19 antibody testing has also been suspended at home and abroad "new crown antidote" research and development is difficult.

The National Institutes of Health (NIH) has called for a moratorium on the recruitment of new patients in Lilly and AbCellera's monoclonal antibody (LY-CoV555) treatment trial (ACTIV-3) for COVID-19 hospitalized patients.
In an emailed communication with CNBC television on Tuesday, a Lilly spokesman said the trial's independent Data Security Monitoring Committee (DSMB) recommended that the company suspend the recruitment of new patients, adding: "Lilly supports the prudent decision of the independent DSMB to ensure the safety of participants in the program."
noted that just the day before, Johnson and Johnson had been asked to suspend an ongoing clinical trial of the new corona vaccine because of unexplained symptoms in a patient involved in the study.
new coronal antibody test on Lilly has been suspended, and it is not clear why.
, both Lilly and NIH mentioned potential safety issues, which seemed to indicate a difference in efficacy between the two groups due to potential side effects of the drug.
NIH said the trial's DSMB indicated that the study had reached a pre-set safety warning line five days after treatment, but the agency did not specify whether the LY-CoV555 group in the trial or patients in the placebo group exceeded the safety threshold.
In addition, 326 patients who had already participated in the trial would not be interrupted, and researchers would further advance the trial in this group, with DSMB meeting again with the experimenters on October 26 to discuss the issues related to the trial.
Lilly's COVID-19 antibody has been the subject of concern because the treatment may help reduce the number of viruses in patients' nasal swabs and reduce hospitalization rates.
LY-CoV555 is an effective monoclonal antibody to IgG1 that directly inhibits the echithrin of sars-CoV-2 virus.
, clinical trials of COVID-19 therapies and vaccines are still undergoing extensive shoulder review.
path to new crown vaccines for major pharmaceutical companies seems to be not going well.
AstraZeneta announced on September 8th that it would suspend an ongoing vaccine trial after a volunteer who had been vaccinated in a new crown vaccine trial developed by the company in partnership with Oxford University developed the disease.
is the first new crown-candidate vaccine to be suspended from Phase III clinical trials.
week, AstraZeneta's clinical trials in the UK and else parts of the country have resumed, and trials in the US have yet to restart, pending regulatory review.
Johnson and Johnson announced on the 12th of this month that the company plans to suspend ongoing clinical trials of the new coronary vaccine because of "unexplained symptoms" of a volunteer involved in the study.
said in a statement that the company is reviewing and evaluating the volunteer's condition.
Johnson, citing privacy concerns, did not specify the volunteer's symptoms.
it is understood that Johnson and Johnson has now shut down the online system for recruiting volunteers.
, Johnson and Johnson said the "research pause" is not the same as the "regulatory pause" required by the FDA.
the company stressed that so-called adverse events - symptoms, accidents and other adverse medical outcomes - are expected to be part of clinical studies, and highlighted the difference between research suspension and clinical trial suspension, a vaccine study that has not yet entered clinical suspension.
the current domestic trial of the new crown vaccine also seems to have some problems.
, there are media reports that the domestic well-known pharmaceutical companies of the new crown vaccine has been open in Beijing, Wuhan, the two places to make an appointment, specifically through the corporate website or scanning enterprises to provide two-dimensional code for the appointment, and the appointment will be notified after two weeks, and to the designated place of injection.
, however, according to Sina Pharmaceuticals, the company's vaccine is still in clinical trial stage, is not yet on the market, how can this open the appointment? READ MORE: Vaccines are not on the market. We have not yet been informed of the exact circumstances.
From the research and development situation at home and abroad, although the current global epidemic is not optimistic, the domestic even about to usher in a second wave of outbreaks, the new crown pneumonia "antidote" research and development supervision still can not be taken lightly, still need a footprint, steady forward.
source: 1. Another day, another delay: NIH halts phase 3 study of Lilly COVID-19 antibody2. NIH paused Eli Lilly Covid-19 antibody trial because of safety concerns.